Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Prostate cancer

177Lu-PSMA-617 extends progression-free survival in taxane-naive mCRPC

Nature Reviews Urology volume 21, page 706 (2024)Cite this article

Subjects

Access through your institution
Buy or subscribe

A new phase III, randomized, controlled trial was carried out to assess the efficacy of 177Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer (mCRPC). A total of 468 patients with PSMA+ mCRPC who experienced disease progression after receiving an androgen receptor pathway inhibitor (ARPI) were randomly allocated to receive 177Lu-PSMA-617 or a different ARPI. Treatment with 177Lu-PSMA-617 resulted in improved median radiographic progression-free survival (PFS) compared with a change of ARPI (11.60 months (95% CI 9.30–14.19) versus 5.59 months (95% CI 4.21–5.95)), with a good safety profile. These results showed that 177Lu-PSMA-617 prolonged radiographic PFS and could be a valid therapeutic alternative for patients considered for a change of ARPI.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

  • Morris, M. J. et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404, 1227–1239 (2024)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Urology https://www.nature.com/nrurol/

    Maria Chiara Masone

Authors
  1. Maria Chiara Masone
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Maria Chiara Masone.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Masone, M.C. 177Lu-PSMA-617 extends progression-free survival in taxane-naive mCRPC. Nat Rev Urol 21, 706 (2024). https://doi.org/10.1038/s41585-024-00970-z

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41585-024-00970-z

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing